array(3) {
["company_details"]=>
array(13) {
["name"]=>
string(29) "Novartis Gene Therapies, Inc."
["slug"]=>
string(19) "a26d9-us-avexis-inc"
["logo"]=>
string(84) "https://images.businessradar.com/linkedin_logos/35cea00f-69c0-468d-b166-ddd4f49dfa0c"
["description"]=>
string(639) "Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development.
Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments.
Around 108,000 people of more than 140 nationalities work at Novartis around the world.
See our community guidelines: http://bit.ly/2JnT2CP"
["address_street"]=>
string(24) "2275 Half Day Rd Ste 200"
["address_place"]=>
string(11) "Bannockburn"
["address_region"]=>
string(8) "Illinois"
["founding_date"]=>
string(10) "2010-02-28"
["website_domain"]=>
string(12) "novartis.com"
["website_url"]=>
string(24) "https://www.novartis.com"
["industry_codes"]=>
array(1) {
[0]=>
string(27) "Pharmaceutical Preparations"
}
["employee_count"]=>
int(219)
["article_count"]=>
int(7823)
}
["articles"]=>
array(9) {
[0]=>
array(7) {
["title_en"]=>
string(85) "Boston Common Asset Management LLC Decreases Stock Holdings in Novartis AG (NYSE:NVS)"
["snippet_en"]=>
string(300) "Boston Common Asset Management LLC lessened its holdings in shares of Novartis AG (NYSE:NVS - Free Report) by 7.4% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 173,545 shares of the company's stock after selling 13,927 shares during"
["url"]=>
string(73) "https://www.marketbeat.com/instant-alerts/nyse-nvs-sec-filing-2024-03-16/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/9d31c5fc-7289-4792-89aa-0b87981aaef2"
["source"]=>
string(14) "marketbeat.com"
["publication_date"]=>
string(10) "2024-03-16"
["categories"]=>
array(5) {
[0]=>
string(11) "Regulations"
[1]=>
string(24) "Quarterly/Annual Figures"
[2]=>
string(18) "General Investment"
[3]=>
string(31) "Financial Update/Profit Warning"
[4]=>
string(12) "Stock Market"
}
}
[1]=>
array(7) {
["title_en"]=>
string(94) "Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results"
["snippet_en"]=>
string(94) "Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results"
["url"]=>
string(53) "https://www.tmcnet.com/usubmit/2024/02/28/9970135.htm"
["image_url"]=>
NULL
["source"]=>
string(10) "tmcnet.com"
["publication_date"]=>
string(10) "2024-02-28"
["categories"]=>
array(2) {
[0]=>
string(24) "Quarterly/Annual Figures"
[1]=>
string(31) "Financial Update/Profit Warning"
}
}
[2]=>
array(7) {
["title_en"]=>
string(69) "Novartis profits below estimates, the stock falls on the stock market"
["snippet_en"]=>
string(127) "2023 net profits at 14.9 billion dollars but the net profit for the quarter, although growing by 6%, missed market expectations"
["url"]=>
string(85) "https://www.ilsole24ore.com/art/novartis-utile-sotto-stime-titolo-cade-borsa-AFIXFyXC"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/db36f9c8-2c44-4bc0-82b1-30550fdc0b22"
["source"]=>
string(15) "ilsole24ore.com"
["publication_date"]=>
string(10) "2024-01-31"
["categories"]=>
array(8) {
[0]=>
string(19) "Economic Conditions"
[1]=>
string(15) "Market Movement"
[2]=>
string(24) "Stock Research & Ratings"
[3]=>
string(24) "Quarterly/Annual Figures"
[4]=>
string(18) "General Investment"
[5]=>
string(12) "Going Public"
[6]=>
string(31) "Financial Update/Profit Warning"
[7]=>
string(12) "Stock Market"
}
}
[3]=>
array(7) {
["title_en"]=>
string(96) "After Novartis' radiotherapy Pluvicto disappoints, CEO touts 'compelling case' for future growth"
["snippet_en"]=>
string(296) "Even though Novartis grew sales and profits in the last quarter of 2023, the magnitude of the increases was not satisfactory to the Swiss pharma's investors. | Novartis grew sales and profits in the last quarter of 2023, but the magnitude of the increases was not satisfactory to the company’ s"
["url"]=>
string(117) "https://www.fiercepharma.com/pharma/pluvicto-missed-blockbuster-mark-novartis-ceo-touts-compelling-case-future-growth"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/365feb59-f900-408a-9b15-80a3b7eccea6"
["source"]=>
string(16) "fiercepharma.com"
["publication_date"]=>
string(10) "2024-01-31"
["categories"]=>
array(3) {
[0]=>
string(24) "Quarterly/Annual Figures"
[1]=>
string(18) "Expansion & Growth"
[2]=>
string(31) "Financial Update/Profit Warning"
}
}
[4]=>
array(7) {
["title_en"]=>
string(58) "Novartis misses Q4 profit expectations as costs disappoint"
["snippet_en"]=>
string(44) "The Latest Breaking, Viral and Trending News"
["url"]=>
string(123) "https://www.shorenewsnetwork.com/2024/01/31/novartis-adj-net-income/logo-is-seen-at-a-building-of-swiss-drugmaker-novartis/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/4b96cf01-a30f-4fe2-a4e8-da71b601cd03"
["source"]=>
string(20) "shorenewsnetwork.com"
["publication_date"]=>
string(10) "2024-01-31"
["categories"]=>
array(2) {
[0]=>
string(24) "Quarterly/Annual Figures"
[1]=>
string(31) "Financial Update/Profit Warning"
}
}
[5]=>
array(7) {
["title_en"]=>
string(51) "Novartis adj net income grows 6%, below market view"
["snippet_en"]=>
string(255) "By Ludwig Burger FRANKFURT (Reuters) -Novartis on Wednesday reported a gain of 6% in fourth-quarter adjusted net income, helped by cost cuts and strong growth of recently launched drugs. Core net income for the quarter came in at $3.13 billion, the Swi..."
["url"]=>
string(78) "https://whbl.com/2024/01/31/novartis-adj-net-income-grows-6-below-market-view/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/edab7310-5f16-47cb-8906-c5704ab40505"
["source"]=>
string(8) "whbl.com"
["publication_date"]=>
string(10) "2024-01-31"
["categories"]=>
array(4) {
[0]=>
string(14) "Product Launch"
[1]=>
string(24) "Quarterly/Annual Figures"
[2]=>
string(15) "Market Movement"
[3]=>
string(31) "Financial Update/Profit Warning"
}
}
[6]=>
array(7) {
["title_en"]=>
string(60) "Novartis Misses Q4 net Income Expectations, Extends Forecast"
["snippet_en"]=>
string(139) "Swiss drugmaker Novartis reported a 6% gain in fourth-quarter adjusted net income on Wednesday, helped by cost cuts and strong growth of..."
["url"]=>
string(106) "https://www.gurutrade.com/news/novartis-misses-q4-net-income-expectations-extends-forecast-1706690204.html"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/fed0d389-8654-486b-85df-8e94ccc1a30b"
["source"]=>
string(13) "gurutrade.com"
["publication_date"]=>
string(10) "2024-01-31"
["categories"]=>
array(2) {
[0]=>
string(24) "Quarterly/Annual Figures"
[1]=>
string(31) "Financial Update/Profit Warning"
}
}
[7]=>
array(7) {
["title_en"]=>
string(52) "Safe haven Switzerland – the number 1 can convince"
["snippet_en"]=>
string(147) "Novartis shines with strong annual figures: sales +8%, profit +42%. Despite the price decline, the situation remains bullish. Dividend yield at 3%."
["url"]=>
string(109) "https://www.deraktionaer.de/artikel/aktien/sicherer-hafen-schweiz-die-nummer-1-kann-ueberzeugen-20349106.html"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/fe4c8bb1-69d8-470c-91bf-0491de5ecc62"
["source"]=>
string(15) "deraktionaer.de"
["publication_date"]=>
string(10) "2024-01-31"
["categories"]=>
array(7) {
[0]=>
string(19) "Economic Conditions"
[1]=>
string(25) "Business Model Resilience"
[2]=>
string(10) "Tax Havens"
[3]=>
string(24) "Quarterly/Annual Figures"
[4]=>
string(18) "General Investment"
[5]=>
string(31) "Financial Update/Profit Warning"
[6]=>
string(12) "Stock Market"
}
}
[8]=>
array(7) {
["title_en"]=>
string(53) "Novartis: profitability restrained in the 4th quarter"
["snippet_en"]=>
string(176) "The Novartis laboratory saw its revenues increase by 8% to $11.42 billion in the last quarter of 2023. The basic operating margin (Ebit) a | Rhône FM, the news radio in Valais"
["url"]=>
string(80) "https://www.rhonefm.ch/suisse/novartis-rentabilite-bridee-au-4e-trimestre-286798"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/114233c0-ad7e-47f8-a0e9-e766c4156e86"
["source"]=>
string(10) "rhonefm.ch"
["publication_date"]=>
string(10) "2024-01-31"
["categories"]=>
array(2) {
[0]=>
string(24) "Quarterly/Annual Figures"
[1]=>
string(31) "Financial Update/Profit Warning"
}
}
}
["category_annotations"]=>
array(30) {
[0]=>
array(2) {
["name"]=>
string(12) "Stock Market"
["count"]=>
int(528)
}
[1]=>
array(2) {
["name"]=>
string(5) "Legal"
["count"]=>
int(450)
}
[2]=>
array(2) {
["name"]=>
string(11) "Acquisition"
["count"]=>
int(433)
}
[3]=>
array(2) {
["name"]=>
string(24) "Quarterly/Annual Figures"
["count"]=>
int(306)
}
[4]=>
array(2) {
["name"]=>
string(12) "Board Change"
["count"]=>
int(301)
}
[5]=>
array(2) {
["name"]=>
string(13) "Collaboration"
["count"]=>
int(241)
}
[6]=>
array(2) {
["name"]=>
string(18) "General Investment"
["count"]=>
int(238)
}
[7]=>
array(2) {
["name"]=>
string(17) "Academic Research"
["count"]=>
int(232)
}
[8]=>
array(2) {
["name"]=>
string(18) "Expansion & Growth"
["count"]=>
int(194)
}
[9]=>
array(2) {
["name"]=>
string(5) "R & D"
["count"]=>
int(188)
}
[10]=>
array(2) {
["name"]=>
string(14) "Product Launch"
["count"]=>
int(179)
}
[11]=>
array(2) {
["name"]=>
string(15) "Market Movement"
["count"]=>
int(161)
}
[12]=>
array(2) {
["name"]=>
string(8) "Epidemic"
["count"]=>
int(161)
}
[13]=>
array(2) {
["name"]=>
string(21) "Competitive Behaviour"
["count"]=>
int(160)
}
[14]=>
array(2) {
["name"]=>
string(15) "Deals & Tenders"
["count"]=>
int(142)
}
[15]=>
array(2) {
["name"]=>
string(31) "Financial Update/Profit Warning"
["count"]=>
int(133)
}
[16]=>
array(2) {
["name"]=>
string(10) "Litigation"
["count"]=>
int(130)
}
[17]=>
array(2) {
["name"]=>
string(25) "Business Model Resilience"
["count"]=>
int(125)
}
[18]=>
array(2) {
["name"]=>
string(12) "Going Public"
["count"]=>
int(119)
}
[19]=>
array(2) {
["name"]=>
string(8) "spin-off"
["count"]=>
int(114)
}
[20]=>
array(2) {
["name"]=>
string(24) "Access and affordability"
["count"]=>
int(112)
}
[21]=>
array(2) {
["name"]=>
string(46) "Management of Legal and Regulatory Environment"
["count"]=>
int(108)
}
[22]=>
array(2) {
["name"]=>
string(6) "Merger"
["count"]=>
int(98)
}
[23]=>
array(2) {
["name"]=>
string(24) "Stock Research & Ratings"
["count"]=>
int(98)
}
[24]=>
array(2) {
["name"]=>
string(12) "Staff hiring"
["count"]=>
int(85)
}
[25]=>
array(2) {
["name"]=>
string(8) "Verdicts"
["count"]=>
int(85)
}
[26]=>
array(2) {
["name"]=>
string(7) "Layoffs"
["count"]=>
int(81)
}
[27]=>
array(2) {
["name"]=>
string(15) "Business Ethics"
["count"]=>
int(80)
}
[28]=>
array(2) {
["name"]=>
string(5) "Award"
["count"]=>
int(78)
}
[29]=>
array(2) {
["name"]=>
string(10) "Divestment"
["count"]=>
int(74)
}
}
}
a26d9-us-avexis-inc
Novartis Gene Therapies, Inc.
Location
Illinois
Founded
2010-02-28
Website
https://www.novartis.com
Articles
7823 Articles
Category
Pharmaceutical Preparations
Description
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development.
Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments.
Around 108,000 people of more than 140 nationalities work at Novartis around the world.
See our community guidelines: http://bit.ly/2JnT2CP
Boston Common Asset Management LLC lessened its holdings in shares of Novartis AG (NYSE:NVS - Free Report) by 7.4% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 173,545 shares of the company's stock after selling 13,927 shares during
Even though Novartis grew sales and profits in the last quarter of 2023, the magnitude of the increases was not satisfactory to the Swiss pharma's investors. | Novartis grew sales and profits in the last quarter of 2023, but the magnitude of the increases was not satisfactory to the company’ s
By Ludwig Burger FRANKFURT (Reuters) -Novartis on Wednesday reported a gain of 6% in fourth-quarter adjusted net income, helped by cost cuts and strong growth of recently launched drugs. Core net income for the quarter came in at $3.13 billion, the Swi...
The Novartis laboratory saw its revenues increase by 8% to $11.42 billion in the last quarter of 2023. The basic operating margin (Ebit) a | Rhône FM, the news radio in Valais
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
